Current Headlines

  1. Introducing Latent-X, A Frontier Generative AI Model For Protein Binder Design Accessible Via No-Code Platform For Push-Button Protein Design 7/22/2025

    Today, Latent Labs is launching Latent-X, a frontier AI model for push button protein design, outperforming competing models under identical laboratory conditions.

  2. Answer ALS Launches AI Drug Development Collaboration With GATC Health, Pennington Biomedical Research Center, And Tulane To Advance ALS Treatment Discovery 7/22/2025

    Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases.

  3. New AI Model Makes Drug Discovery Faster, Smarter, And More Transparent 7/22/2025

    A new algorithm could help researchers better predict how molecules bind to proteins —an essential step in designing more effective drugs to treat a wide range of diseases.

  4. Lantern Pharma Secures EU Patent Allowance For LP-284, Bolstering Global IP Position For AI-Developed Cancer Therapy 7/21/2025

    Lantern Pharma Inc. a clinical-stage oncology company leveraging its proprietary RADR artificial intelligence (AI) platform to accelerate drug discovery, today announced that the European Patent Office (EPO) has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284.

  5. Creative Diagnostics Launches HIV Infection Rhesus Monkey Models To Accelerate AIDS Research And Treatment Development 7/21/2025

    As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced its new portfolio of highly specialized HIV Infection Rhesus Monkey Models for scientists and pharmaceutical developers to accelerate HIV/AIDS research.

  6. ImCheck's Announces EMA Orphan Drug Designation For ICT01 As Treatment For Acute Myeloid Leukemia 7/21/2025

    ImCheck Therapeutics today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A) monoclonal antibody designed to selectively activate γ9δ2 T cells, for the treatment of acute myeloid leukemia (AML).

  7. Elix Provides AI Drug Discovery Platform 'Elix Discovery' To Eisai 7/17/2025

    Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix Discovery (https://www.elix-inc.com/platform/), has been adopted by Eisai Co., Ltd. (Headquarters: Tokyo; hereinafter “Eisai”).

  8. New Partnership With Parkinson's Research Foundation To Accelerate Parkinson's Drug Discovery 7/17/2025

    WEHI has formed a partnership with the Parkinson’s Research Foundation with one clear goal: to intensify the search for drug treatments to stop Parkinson’s.

  9. Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development 7/16/2025

    Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities.

  10. C-Path's Translational Therapeutics Accelerator Announces $200,000 Grant For Drug Development Project In Inflammatory Bowel Disease 7/16/2025

    Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $200,000 grant to Carlos Subauste, MD, an internist and infectious disease specialist at University Hospitals Cleveland Medical Center and professor at Case Western Reserve University, to advance a promising new therapy for inflammatory bowel disease (IBD).